PEGBIO Shares Surge on Positive Progress for Diabetes Drug in National Reimbursement Review

Stock News07-02

Shares of PEGBIO CO-B (ASX: 02565) rose more than 5%, trading up 4.13% at HK$5.55 by the latest update, with a turnover of HK$39.02 million.

Key Development

The company recently announced that its core product, Vipeptide Injection (brand name: Paida Kang®), has been included in the preliminary list of drugs for the adjustment of the 2026 National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Formulary and Commercial Insurance Innovative Drug Formulary. It is listed as item 242 under the "Western and Chinese Patent Medicines Outside the Formulary - Basic List," categorized as a Western medicine. It was approved under "Condition 1 for drugs outside the formulary" and is designated as an exclusive product.

Management Perspective

The board believes that passing the preliminary formal review for the 2026 National Reimbursement Drug List adjustment marks a critical step, indicating the product has entered the subsequent evaluation process for national formulary access. This is a pivotal milestone in its post-market access journey.

Potential Impact

Should the product be successfully included in the national formulary, it is expected to significantly enhance payment accessibility, patient affordability, and clinical adoption. This would further unlock its commercial potential in the type 2 diabetes treatment market and positively contribute to the group's revenue growth, cash flow improvement, and the revaluation of its core product portfolio.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116321689?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 13:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116321689","market":"sg","top_or_hot":-1,"title":"PEGBIO Shares Surge on Positive Progress for Diabetes Drug in National Reimbursement Review","media":"Stock News","content":"<p><br><br>\nShares of <b>PEGBIO CO-B</b> (<b>ASX: 02565</b>) rose more than 5%, trading up 4.13% at HK$5.55 by the latest update, with a turnover of HK$39.02 million.<br><br>\n<b>Key Development</b><br><br>\nThe company recently announced that its core product, Vipeptide Injection (brand name: Paida Kang®), has been included in the preliminary list of drugs for the adjustment of the 2026 National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Formulary and Commercial Insurance Innovative Drug Formulary. It is listed as item 242 under the \"Western and Chinese Patent Medicines Outside the Formulary - Basic List,\" categorized as a Western medicine. It was approved under \"Condition 1 for drugs outside the formulary\" and is designated as an exclusive product.<br><br>\n<b>Management Perspective</b><br><br>\nThe board believes that passing the preliminary formal review for the 2026 National Reimbursement Drug List adjustment marks a critical step, indicating the product has entered the subsequent evaluation process for national formulary access. This is a pivotal milestone in its post-market access journey.<br><br>\n<b>Potential Impact</b><br><br>\nShould the product be successfully included in the national formulary, it is expected to significantly enhance payment accessibility, patient affordability, and clinical adoption. This would further unlock its commercial potential in the type 2 diabetes treatment market and positively contribute to the group's revenue growth, cash flow improvement, and the revaluation of its core product portfolio.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PEGBIO Shares Surge on Positive Progress for Diabetes Drug in National Reimbursement Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPEGBIO Shares Surge on Positive Progress for Diabetes Drug in National Reimbursement Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-02 13:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><br><br>\nShares of <b>PEGBIO CO-B</b> (<b>ASX: 02565</b>) rose more than 5%, trading up 4.13% at HK$5.55 by the latest update, with a turnover of HK$39.02 million.<br><br>\n<b>Key Development</b><br><br>\nThe company recently announced that its core product, Vipeptide Injection (brand name: Paida Kang®), has been included in the preliminary list of drugs for the adjustment of the 2026 National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Formulary and Commercial Insurance Innovative Drug Formulary. It is listed as item 242 under the \"Western and Chinese Patent Medicines Outside the Formulary - Basic List,\" categorized as a Western medicine. It was approved under \"Condition 1 for drugs outside the formulary\" and is designated as an exclusive product.<br><br>\n<b>Management Perspective</b><br><br>\nThe board believes that passing the preliminary formal review for the 2026 National Reimbursement Drug List adjustment marks a critical step, indicating the product has entered the subsequent evaluation process for national formulary access. This is a pivotal milestone in its post-market access journey.<br><br>\n<b>Potential Impact</b><br><br>\nShould the product be successfully included in the national formulary, it is expected to significantly enhance payment accessibility, patient affordability, and clinical adoption. This would further unlock its commercial potential in the type 2 diabetes treatment market and positively contribute to the group's revenue growth, cash flow improvement, and the revaluation of its core product portfolio.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1116321689","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116321689","pubTimestamp":1782971187,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":" Shares of PEGBIO CO-B (ASX: 02565) rose more than 5%, trading up 4.13% at HK$5.55 by the latest update, with a turnover of HK$39.02 million. Key Development The company recently announced that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"161726":"生物医药","399441":"生物医药","02565":"派格生物医药-B","BK4581":"高盛持仓","BK4588":"碎股","BK1161":"生物科技","BK4585":"ETF&股票定投概念","XBI":"SPDR S&P Biotech ETF","VXUS":"国际股票ETF-Vanguard"},"translate_title":"糖尿病药物在国家报销审查中取得积极进展，PEGBIO股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161726":1,"399441":1,"XBI":1,"02565":1,"VXUS":1},"content_text":"Shares of PEGBIO CO-B (ASX: 02565) rose more than 5%, trading up 4.13% at HK$5.55 by the latest update, with a turnover of HK$39.02 million.\nKey Development\nThe company recently announced that its core product, Vipeptide Injection (brand name: Paida Kang®), has been included in the preliminary list of drugs for the adjustment of the 2026 National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Formulary and Commercial Insurance Innovative Drug Formulary. It is listed as item 242 under the \"Western and Chinese Patent Medicines Outside the Formulary - Basic List,\" categorized as a Western medicine. It was approved under \"Condition 1 for drugs outside the formulary\" and is designated as an exclusive product.\nManagement Perspective\nThe board believes that passing the preliminary formal review for the 2026 National Reimbursement Drug List adjustment marks a critical step, indicating the product has entered the subsequent evaluation process for national formulary access. This is a pivotal milestone in its post-market access journey.\nPotential Impact\nShould the product be successfully included in the national formulary, it is expected to significantly enhance payment accessibility, patient affordability, and clinical adoption. This would further unlock its commercial potential in the type 2 diabetes treatment market and positively contribute to the group's revenue growth, cash flow improvement, and the revaluation of its core product portfolio.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116321689","isCrawlerRequest":true}